- Home
- CLPR vs CRVO Comparison
CLPR vs CRVO Comparison
Compare CLPR & CRVO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CLPR | CRVO |
|---|---|---|
| Founded | 2015 | 2001 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 51.8M | 47.7M |
| IPO Year | 2015 | 2011 |
Fundamental Metrics
Financial Performance| Metric | CLPR | CRVO |
|---|---|---|
| Price | $2.95 | $3.78 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $23.00 |
| AVG Volume (30 Days) | 66.6K | ★ 92.8K |
| Earning Date | 05-11-2026 | 03-17-2026 |
| Dividend Yield | ★ 12.58% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $109,997,000.00 | $4,006,510.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 5.82 | N/A |
| 52 Week Low | $2.97 | $3.58 |
| 52 Week High | $4.61 | $14.00 |
Technical Indicators
Market Signals| Indicator | CLPR | CRVO |
|---|---|---|
| Relative Strength Index (RSI) | 35.99 | 35.59 |
| Support Level | N/A | $3.58 |
| Resistance Level | $3.96 | $5.24 |
| Average True Range (ATR) | 0.12 | 0.39 |
| MACD | 0.00 | 0.00 |
| Stochastic Oscillator | 10.29 | 2.78 |
Price Performance
Historical ComparisonAbout CLPR Clipper Realty Inc.
Clipper Realty Inc is a self-administered and self-managed real estate company. It acquires, owns, manages, operates, and repositions multifamily residential and commercial properties in the New York metropolitan area, with a portfolio in Manhattan and Brooklyn. It has classified its reporting segments into Residential Rental Properties and Commercial Rental Properties. The company derives its revenue mostly from the Residential segment.
About CRVO CervoMed Inc.
CervoMed Inc is a clinical stage biotechnology company. It is focused on developing treatments for age-related neurologic disorders. The company's product candidate, Neflamapimod has the potential to treat and improve synaptic dysfunction, the reversible aspect of the underlying disease processes in DLB and certain other neurological disorders.